These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8054911)

  • 21. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
    Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor.
    Kanda Y; Sakamaki H; Sao H; Okamoto S; Kodera Y; Tanosaki R; Kasai M; Hiraoka A; Takahashi S; Miyawaki S; Kawase T; Morishima Y; Kato S;
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):881-9. PubMed ID: 16275591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Big BU/CY is associated with a favorable long-term outcome in patients allotransplanted for chronic myelogenous leukemia in chronic phase.
    Bonini A; Bandini G; Rosti G; Rondelli D; Testoni N; Remiddi C; Motta MR; Rizzi S; Mangianti S; Campanini E; Zuffa E; Tura S
    Bone Marrow Transplant; 1998 Jun; 21(11):1085-9. PubMed ID: 9645569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic bone marrow transplantation from HLA-identical siblings following conditioning with busulphan and cyclophosphamide.
    Wiktor-Jedrzejczak W; Szczylik C; Matej H; Pojda Z; Ratajczak MZ; Myc A; Siekierzyński M; Kansy J; Kłos M; Rybicki Z
    Arch Immunol Ther Exp (Warsz); 1991; 39(4):441-7. PubMed ID: 1821620
    [No Abstract]   [Full Text] [Related]  

  • 25. Successful allogeneic bone marrow transplantation in juvenile CML: conditioning or graft-versus-leukaemia effect?
    Rassam SM; Katz F; Chessells JM; Morgan G
    Bone Marrow Transplant; 1993 Mar; 11(3):247-50. PubMed ID: 8467291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
    Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ
    Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer.
    Klumpp TR; Mangan KF; Glenn LD; Macdonald JS
    Bone Marrow Transplant; 1993 Apr; 11(4):337-9. PubMed ID: 8097937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects.
    Thall PF; Champlin RE; Andersson BS
    Bone Marrow Transplant; 2004 Jun; 33(12):1191-9. PubMed ID: 15122310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A preparatory regimen of total body irradiation, busulphan and melphalan for allogeneic bone marrow transplantation in childhood high-risk leukemia and lymphoma.
    Yoshihara T; Naya M; Tsunamoto K; Hojo M; Hibi S; Morimoto A; Todo S; Imashuku S
    Anticancer Res; 2003; 23(2C):1739-42. PubMed ID: 12820450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of allogeneic bone marrow transplant in chronic myeloid leukaemia following conditioning with busulfan and cyclophosphamide.
    Saikia TK; Advani SH; Parikh PM; Bapna A; Somjee S; Mukhopadhyay A; Gopal R; Nair CN
    J Assoc Physicians India; 1999 Aug; 47(8):770-3. PubMed ID: 10778619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bone marrow re-transplantation following a busulfan and cyclophosphamide regimen].
    Hirasawa A; Hiruma K; Wakita H; Endo N; Takabayashi K; Oh H; Yoshida S; Aotsuka N; Asai T; Igarashi T
    Rinsho Ketsueki; 1990 Jul; 31(7):974-8. PubMed ID: 2214194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.
    Bertz H; Potthoff K; Finke J
    J Clin Oncol; 2003 Apr; 21(8):1480-4. PubMed ID: 12697870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
    Ritchie DS; Szer J; Roberts AW; Shuttleworth P; Grigg AP
    Bone Marrow Transplant; 2002 Nov; 30(10):645-50. PubMed ID: 12420202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The development of busulfan/cyclophosphamide preparative regimens.
    Santos GW
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):12-6; quiz 17. PubMed ID: 8342070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.